Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02245360 | Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis | PHASE3 | COMPLETED | 107 | — | — | Oct 1, 2014 | Mar 1, 2015 | Jan 11, 2016 | 15 | Russia |
measurement of IgG4 in serum
| Arm | Type | Description |
|---|---|---|
| Grass tablet 75,000 SQ-T | EXPERIMENTAL | Grass tablet 75,000 Standardized Quality units Tablet (SQ-T) |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Phleum pratense grass pollen allergen extract | DRUG | Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days |
| placebo | DRUG | placebo tablet given once daily over 60 days |
Inclusion Criteria: * clinical history consistent with grass pollen-induced allergic rhinoconjunctivitis. * Use of symptomatic treatment of grass pollen-induced allergic rhinoconjunctivitis. * Positive skin prick test response (wheal diameter ≥3 mm) to Phleum pratense. * If asthma, daily use of Inh...